Find research datasets worth reusing

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

ClinicalTrials.gov study NCT01040832. IPD Sharing: Not stated. Countries: 8. Publications: 1.

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

ClinicalTrials.gov study NCT02641093. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

ClinicalTrials.gov study NCT00971932. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

ClinicalTrials.gov study NCT00588770. IPD Sharing: Not stated. Countries: 3. Publications: 1.

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

ClinicalTrials.gov study NCT02573493. IPD Sharing: NO. Countries: 1. Publications: 1.

Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

ClinicalTrials.gov study NCT00705016. IPD Sharing: Not stated. Countries: 9. Publications: 1.

Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma

ClinicalTrials.gov study NCT02325401. IPD Sharing: Not stated. Countries: 1. Publications: 1.

opencc-by-4.0Mar 2021View details →

zenodo32/100

Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma

Data supporting the findings of the paper "<a href="https://doi.org/10.1038/s41698-022-00253-z">Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma</a>." Files include output of multiplex immunohistochemistry computational image processing workflow for each tumor region and survival data for each patient. The code used to produce the results of this study is available at: <a href="https://github.com/kblise/HNSCC_mIHC_paper">https://github.com/kblise/HNSCC_mIHC_paper</a>. Notes about data files: <ul> <li>clinicalData.csv = Contains the following columns for each tumor region: <ul> <li>sample = tumor region ID</li> <li>dtr = Progression free survival (days to recurrence)</li> <li>tnm = TNM stage</li> <li>anatomy = anatomic site of resection</li> <li>tx = therapy administered</li> <li>area = area in mm2 of tissue region</li> </ul> </li> <li>pt .csv files = Matrix of single cells (rows) and marker expression (columns). One file per tumor region (n=47). Other columns include: <ul> <li>class = Cell phenotype assigned via hierarchical gating strategy (see below for classes)</li> <li>Location_Center_X and Location_Center_Y = Cartesian coordinates of cell center</li> <li>Cellsp_PD1p = PD-1 expression; 1 = PD-1+, 0 = PD-1-</li> <li>Cellsp_PDL1p = PD-L1 expression; 1 = PD-L1+, 0 = PD-L1-</li> <li>Cellsp_KI67p = Ki-67 expression; 1 = Ki-67+, 0 = Ki-67-</li> </ul> </li> </ul> Classes, corresponding cell phenotype, and gating strategy used: <ul> <li>A = CD8+ T Cell (CD45+ CD20- CD3+ CD8+)</li> <li>B = CD4+ T Helper (CD45+ CD20- CD3+ CD8- FOXP3-)</li> <li>C = B Cell (CD45+ CD20+)</li> <li>D = Macrophage (CD45+ CD20- CD3- CD66B- CD68+)</li> <li>E = Other Immune (CD45+ CD20- CD3- CD66B- CD68- MHCII- CD8- FOXP3-)</li> <li>F = Other Non-Immune (CD45- PANCK- αSMA-) - excluded from analysis</li> <li>G = Noise - excluded from analysis</li> <li>H = Neoplastic Tumor (CD45- PANCK+)</li> <li>J = Granulocyte (CD45+ CD20- CD3- CD66B+)</li> <li>K = CD4+ Regulatory T Cell (CD45+ CD20- CD3+ CD8- FOXP3+)</li> <li>N = αSMA+ Mesenchymal (CD45- PANCK- αSMA+)</li> <li>X = Antigen Presenting Cell (CD45+ CD20- CD3- CD66B- CD68- MHCII+)</li> </ul>

A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

ClinicalTrials.gov study NCT01046266. IPD Sharing: Not stated. Countries: 5. Publications: 1.

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck

ClinicalTrials.gov study NCT06016413. IPD Sharing: UNDECIDED. Countries: 1. Publications: 14.

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)

ClinicalTrials.gov study NCT05136768. IPD Sharing: NO. Countries: 1. Publications: 3.

Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma

ClinicalTrials.gov study NCT02119559. IPD Sharing: Not stated. Countries: 1. Publications: 2.

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

ClinicalTrials.gov study NCT05328024. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma

ClinicalTrials.gov study NCT04428047. IPD Sharing: NO. Countries: 1. Publications: 1.

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

ClinicalTrials.gov study NCT01737008. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

ClinicalTrials.gov study NCT00652613. IPD Sharing: Not stated. Countries: 1. Publications: 1.

A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M S

ClinicalTrials.gov study NCT01911598. IPD Sharing: Not stated. Countries: 2. Publications: 1.

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

ClinicalTrials.gov study NCT03082534. IPD Sharing: NO. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

ClinicalTrials.gov study NCT02255097. IPD Sharing: YES. Countries: 0. Publications: 4.

Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)

ClinicalTrials.gov study NCT00623558. IPD Sharing: Not stated. Countries: 1. Publications: 1.